Cognitive phenotypes, brain morphometry and the detection of cognitive decline in preclinical AD

Veterans Affairs San Diego Healthcare System, San Diego, CA 92151, USA.
Behavioural neurology (Impact Factor: 1.45). 01/2009; 21(1):29-37. DOI: 10.3233/BEN-2009-0229
Source: PubMed


Identifying a preclinical phase of Alzheimer's Disease (PCAD) that is distinct from cognitive changes in healthy aging continues to be a major research focus. Combining neuropsychological and neuroimaging methodologies should improve our ability to differentiate healthy from pathological aging, although studies that utilize both methods often result in equivocal findings, possibly due to variability in cognitive test performance that may be capturing distinct phenotypes. One method of capturing this cognitive variability is to utilize contrasting neuropsychological tests to identify subgroups representative of distinct cognitive phenotypes, and determine whether differences in brain morphometry support these classifications. We review several approaches to defining cognitive subgroups, and we consider the possibility that cognitive asymmetry might provide one means of identifying both functional and structural changes associated with aging and dementia.

Download full-text


Available from: Christine Fennema-Notestine
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a common progressive neurodegenerative disorder that is not currently diagnosed until a patient reaches the stage of dementia. There is a pressing need to identify AD at an earlier stage, so that treatment, when available, can begin early. Quantitative structural MRI is sensitive to the neurodegeneration that occurs in mild and preclinical AD, and is predictive of decline to dementia in individuals with mild cognitive impairment. Objective evidence of ongoing brain atrophy will be critical for risk/benefit decisions once potentially aggressive, disease-modifying treatments become available. Recent advances have paved the way for the use of quantitative structural MRI in clinical practice, and initial clinical use has been promising. However, further experience with these measures in the relatively unselected patient populations seen in clinical practice is needed to complete translation of the recent enormous advances in scientific knowledge of AD into the clinical realm.
    Preview · Article · Nov 2010 · Expert Review of Neurotherapeutics
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dr. Peter S. Spencer, a pioneering neurotoxicologist of international renown, delivered the keynote address at the 2010 Joint Scientific Symposium of the Society of Toxicologic Pathology (STP) and the International Federation of Societies of Toxicologic Pathologists (IFSTP). He has made many landmark discoveries during his four-decade career. Dr. Spencer's address communicated several fundamental principles of past and present toxicologic neuropathology research, and he also predicted future trends in the field. First, classic approaches to toxicologic neuropathology emphasized morphologic techniques such as light microscopic and ultrastructural assessment. However, neuropathology methods alone rarely reveal the mechanism(s) and etiology of neurotoxic conditions, so neurotoxicity problems are now being investigated using a multidisciplinary approach in which neuropathologic assessment is but one component of the analysis. The two primary trends for future toxicologic neuropathology investigations, in both animals and humans, will be an increased use of noninvasive neural imaging and greater preference for in situ molecular ("omic") methods, which provide functional information in a structural context. These trends will significantly enhance the ability of scientists to translate animal data to human situations, thereby improving our understanding of disease mechanisms and facilitating efforts to design new therapies for neural diseases.
    Full-text · Article · Nov 2010 · Toxicologic Pathology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dementia of the Alzheimer's type (DAT) is a major public health threat in developed countries where longevity has been extended to the eighth decade of life. Estimates of prevalence and incidence of DAT vary with what is measured, be it change from a baseline cognitive state or a clinical diagnostic endpoint, such as Alzheimer's disease. Judgment of what is psychometrically "normal" at the age of 80 years implicitly condones a decline from what is normal at the age of 30. However, because cognitive aging is very heterogeneous, it is reasonable to ask "Is 'normal for age' good enough to screen for DAT or its earlier precursors of cognitive impairment?" Cost containment and accessibility of ascertainment methods are enhanced by well-validated and reliable methods such as screening for cognitive impairment by telephone interviews. However, focused assessment of episodic memory, the key symptom associated with DAT, might be more effective at distinguishing normal from abnormal cognitive aging trajectories. Alternatively, the futuristic "Smart Home," outfitted with unobtrusive sensors and data storage devices, permits the moment-to-moment recording of activities so that changes that constitute risk for DAT can be identified before the emergence of symptoms.
    Full-text · Article · Jan 2011 · Alzheimer's & dementia: the journal of the Alzheimer's Association
Show more